Article Text

other Versions

PDF
Thick Hearts, High Stakes, Great Uncertainties: Screening Athletes for Hypertrophic Cardiomyopathy
  1. Aaron Baggish (abaggish{at}partners.org)
  1. Massachusetts General Hospital, United States
    1. P D Thompson (pthomps{at}harthosp.org)
    1. Hartford Hospital, United States

      Abstract

      In 1958, British pathologist Donald Teare described a family in which 8 sudden death victims had marked asymmetric hypertrophy of the left ventricle,[1] a condition now known as hypertrophic cardiomyopathy (HCM). Though much has been learned about HCM, a number of issues remain unresolved, including how best to prevent HCM-related sudden cardiac death (SCD) in young athletes. As recently as the 2008 British Cardiovascular Society meeting, experts in cardiovascular medicine continued this lively debate.[2] This editorial seeks to summarize the key issues regarding the detection and management of HCM in athletes.

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.